vimarsana.com

Page 15 - முன்னேற்றங்கள் பார்மா அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Strides Pharma: Strides Pharma gets USFDA nod for generic drug

Strides Pharma receives USFDA approval for Ursodiol Capsules

Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Ursodiol Capsules USP, 300 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Actigall Capsules, 300 mg, of Allergan Sales, LLC. According to IQVIA MAT November 2020 data, the US market for Ursodiol Capsules USP, 300 mg is approximately US$ 45 Mn. The product will be manufactured at the company s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. The company has 127 cumulative ANDA filings with USFDA of which 96 ANDAs have been approved

softgel capsule market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2023

softgel capsule market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2023
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

India Ratings upgrades Strides Pharma Science Limited to IND A+ , Outlook Stable

Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Truvada Tablets, 200 mg/300 mg, of Gilead Sciences. According to IQVIA MAT November 2020 data, the US market for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is approximately US$ 2.4 Bn. The product will be manufactured at the company s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. The company has 127 cumulative ANDA filings with USFDA of which 95 ANDAs have been approved

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.